Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-26
2011-12-20
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S272000, C514S275000, C514S252050, C514S252140, C514S235800, C514S227800, C514S252180, C514S218000, C544S238000, C544S239000, C544S241000, C544S224000, C544S232000, C544S122000, C544S321000, C544S323000, C544S330000, C544S332000, C544S295000, C544S123000, C544S058400, C544S324000, C544S296000, C558S403000, C560S043000, C564S244000, C564S306000, C564S305000, C564S191000, C568S949000
Reexamination Certificate
active
08080551
ABSTRACT:
HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.
REFERENCES:
patent: 3459731 (1969-08-01), Gramera et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 5958935 (1999-09-01), Davis et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6838464 (2005-01-01), Pease et al.
patent: 6949544 (2005-09-01), Bethiel et al.
patent: 6982091 (2006-01-01), Pauletti et al.
patent: 7060827 (2006-06-01), Singh et al.
patent: 7125879 (2006-10-01), Guillemont et al.
patent: 7399856 (2008-07-01), Schils et al.
patent: 2006/0034797 (2006-02-01), Arien et al.
patent: 2009/0148531 (2009-06-01), Hantke et al.
patent: 2324919 (1999-10-01), None
patent: 19945982 (1999-09-01), None
patent: 19945982 (2001-03-01), None
patent: 2341 (1979-06-01), None
patent: 0002341 (1982-01-01), None
patent: 1002795 (1999-05-01), None
patent: 0945443 (1999-09-01), None
patent: 1002795 (2000-05-01), None
patent: 2000-35628 (2000-02-01), None
patent: WO 97/18839 (1997-05-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 97/24350 (1997-07-01), None
patent: WO 98/41512 (1998-09-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/27825 (2000-05-01), None
patent: WO0027825 (2000-05-01), None
patent: WO 00/53610 (2000-09-01), None
patent: WO 00/62778 (2000-10-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/22938 (2001-04-01), None
patent: WO 01/23362 (2001-04-01), None
patent: WO 01/60816 (2001-08-01), None
patent: WO 01/64654 (2001-09-01), None
patent: WO 01/85700 (2001-11-01), None
patent: WO 02/08226 (2002-01-01), None
patent: WO 02/70470 (2002-09-01), None
patent: WO 03/016306 (2003-02-01), None
patent: WO 2004/16581 (2003-02-01), None
patent: WO 2004/50058 (2004-06-01), None
patent: WO 2005/021001 (2005-03-01), None
Ludocici, et al., Bioorg. & Med. Chem. Letters (2001), 11(17), 2235-2239.
Supuran, et al., J. of Enzyme Inhibition (2000), 15(4), 391-401.
Miles, Community Pract., vol. 78, Aug. 2005, pp. 292-294 ( Medline abstract), 2005.
Denton, et al., PLoS Medicine, Jan. 14, 2008.
Mayo Clinic, HIV infection symptoms according to infection stage; <http://www.mayoclinic.com/health/hiv-aids/DS00005/DSECTION=symptoms>, updated Jun. 20, 2008, downloaded Feb. 27, 2009.
D'Auria, M., et al. “Photochemical Dimerization in Solution of Arylacrylonitrile Derivatives”, Tetrahedron, vol. 53, No. 51, pp. 17307-17316 (1997).
Denton, et al. “Antiretroviral Pre-Exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice”, PLoS Medicine (Jan. 14, 2008).
Gilead Press Release XP-002314669 Oct. 24, 2005.
Koyanagi, Y., et al. “Selective Cytotoxicity of Aids Virus Infection Towards HTLV1-Transformed Cell Lines”, Int. J. Cancer: 36, pp. 445-451 (1985).
Larock, R. C. “Interconversion of Nitriles Casiooxylic Acids and Derivatives”, John Wiley & Sons, Inc. pp. 1983-1985 1999.
Ludovici, D., et al. “Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues”, Bioorganic & Medicinal Chemistry Letters, vol. 11 pp. 2235- 2239 (2001).
Mayo Clinic, HIV Infection Symptoms According to Infection Stage, www.mayoclinic.com/health/hiv-aids/DS00005/DSECTION-symptoms (Nov. 2, 2009).
Miles, K., “The Growing HIV Pandemic”, HIV Diagnoses: Community Practitioner (2005) vol. 78, No. 8 pp. 292-294.
Pavia, A., “Abacavir/Lamiviudne in Connection With Efavirenz, Amprenavir/Ritonavir or Stavudine”, XP 002274550, The XIV International AIDS Conference Jul. 9, 2002.
Squires, K., “An Introduction to Nucleoside and Nucleotide Analogues”, Antiviral Therapy, 6 Suppl.3, XP 009042950 pp. 1-14 2001.
Supuran, Cl., et al. “Carbonic Anhyddrase Inhibitors: Synthesis of Sulfonamides Incorporating 2,4,6-Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and In Vivo Selectively for the Membrane-Bound (CA IV) Versus the Cytosolic (CA 1 and CA II) Isozymes”, Journal of Enzyme Inhibitor and Medicinal Chemistry vol. 15, pp. 381-340 (2000).
Young, B., “Can Abacavir Be Given Once-A-Day?” the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy XP-002274551 Sep. 16, 2003.
International Search report, mailing date Nov. 26, 2002, for corresponding Application No. PCT/EP2002/08953.
International Preliminary Examination Report dated Dec. 3, 2003 for corresponding Appln. No. PCT/EP2002/08953.
European Search Report dated Dec. 5, 2001 for corresponding Application No. EP 01203090.4.
International Search Report, mailing date Feb. 7, 2005, for corresponding Application No. PCT/EP2004/052028 (related subject matter).
Canadian Search Report dated Feb. 19, 2007 for corresponding Application No. CA 2,452,217.
International Search Report dated Nov. 6, 2003 for related International Application No. PCT/EP2003/50366.
International Preliminary Examination Report dated Nov. 30, 2004 for corresponding Appin. No. PCT/EP2003/50366.
Office Action dispatched May 12, 2009 for corresponding Japanese Patent Application No. 521229/03.
Gennaro, AR “Remington Pharmacy”, 19thedition, Medica Panmericana, 1995, pp. 230-235, 245, and 2226-2234. English translation and Certfication attached.
Arts, legal representative Frank Xavier Jozef Herwig
Daeyaert Frederik Frans Desire
De Jonge Marc Rene
Guillemont Jérôme Emile Georges
Heeres Jan
Berch Mark L
Jaisle Cecilia M
Janssen Pharmaceutica N.V.
Shah Rajiv S.
LandOfFree
HIV inhibiting pyrimidines derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV inhibiting pyrimidines derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV inhibiting pyrimidines derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4253323